Sofia Paul

TL;DR: Raloxifene favorably alters biochemical markers of cardiovascular risk by decreasing LDL-C, fibrinogen, and lipoprotein(a), and by increasing HDL2-C without raising triglycerides.

TL;DR: HRT and raloxifene lower serum homocysteine levels to a comparable extent in postmenopausal women, and the relationship between elevated C-reactive protein levels with HRT and cardiovascular disease events requires further study.

TL;DR: The Raloxifene Use for The Heart (RUTH) trial is designed to determine whether raloxIFene 60 mg/day compared with placebo reduces the risk of the coronary events and invasive breast cancer in women at risk for a major coronary event.

TL;DR: Raloxifene does not prevent ovulation in women with normal menstrual cycles; ovarian estrogen production will continue, and in some cases increase, in response to ralox ifene; and antiestrogenic effects of ral oxifene on the endometrium are subtle in the endocrine milieu of normal to high circulating estradiol concentrations.

TL;DR: Future trials in the second-line setting should stratify patients by gender, stage at diagnosis, performance status, PS, and best response to first-line therapy.